SPONSORED CONTENT
Many people have been losing sleep thinking about how they should move forward in the current 340B environment. Over the last 18 months, it has felt like an external force is around every corner, pushing or pulling covered entities into new areas of discomfort.
During these turbulent times, it can help to find partners who
…
Q: Where did you complete your professional training?
I graduated with an Honours Bachelor’s of Science from York University in Toronto, Canada in 1997 and a Bachelor of Science in Pharmacy
…SPONSORED CONTENT
Commencing in the early 1970s, specialty pharmacy was originally intended for patients requiring unique therapies for various conditions. Initially this included mainly infusions for hemophilia, cancer, or malnutrition[i]. Most of these offerings came with high costs (many of which can now be offset by copay
…SPONSORED CONTENT
For 340B program directors, complying with the U.S. Health Resources & Services Administration’s (HRSA’s) requirements is top of mind, all the time. That’s partly because maintaining their employer’s 340B program directly ties to profitability and sometimes survival. Covered entities need 340B revenue to meet the program’s purpose “to stretch scare resources
…
SPONSORED CONTENT
TIP: When it comes to duplicate discount prevention, don’t assume that all 340B drugs are billed to Medicaid using the same NPI. Routine
SPONSORED CONTENT
The healthcare industry continues to evolve. We see this evolution range from technology advancements and self-serve digital platforms to competing payer coverages and vast access to both acute and maintenance medications. Throughout this evolution, the patient experience and continuity of care are crucial to supporting a patient’s journey throughout the healthcare ecosystem.
… SPONSORED CONTENT
TIP: The key to unlocking the full potential of your program starts with complete understanding of your data.
SPONSORED CONTENT
TIP: If your entity engages a firm to independently audit your 340B Program, follow through on the auditor’s recommendations in a timely manner.
SPONSORED CONTENT
Many covered entities are not aware of the opportunity to capture referral prescriptions. This includes ones that were initially determined to be non-eligible by your TPA but after a closer look in your EMR are deemed to be eligible. Don’t miss out on this valuable source of revenue for your 340B program by
… SPONSORED CONTENT
TIP: Don’t forget that in a replenishment model, 340B purchases are primarily made after determining eligibility through accumulated eligibility.
×
*Sign up for news summaries and alerts from 340B Report
